The National Kidney Foundation has recommended that the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation replace the Modification of Diet in Renal Disease (MDRD) Study equation. Before implementing this change in the Kidney Early Evaluation Program (KEEP), we compared characteristics of reclassified individuals and mortality risk predictions using the new equation.
G lomerular filtration rate (GFR) is the best over-
all index of kidney function. Decreased GFR is associated with increased risk of complications related to kidney disease, including uremic manifestations of kidney disease, acute kidney injury, kidney failure, and cardiovascular disease. GFR also is important for making many clinical decisions, including listing for kidney transplant, medication dose adjustment, and avoidance of toxic medications. GFR most often is assessed using estimating equations derived from serum levels of endogenous filtration markers, the most common being creatinine.
The most commonly used estimating equation is the Modification of Diet in Renal Disease (MDRD) Study equation, developed from 1,628 people with chronic kidney disease (CKD) with a mean measured GFR of 40 mL/min/1.73 m 2 . 1 It has been shown to be valid in similar populations, but to underestimate measured GFR at the higher range, 2 around 60 mL/ min/1.73 m 2 , leading to misclassification to a lower category and thus overdiagnosis of CKD. The CKD Epidemiology Collaboration (CKD-EPI) equation was developed in 8,254 people and validated in a separate data set of 3,896. 3 Both the development and validation data sets included people with and without kidney disease and a wide range of GFRs, with mean measured GFR of 68 mL/min/1.73 m 2 . The CKD-EPI equation has been shown to be a better estimate of measured GFR than the MDRD Study equation, particularly at higher levels.
Approximately 80% of clinical laboratories currently report estimated GFR (eGFR) when serum creatinine is measured. 4 Most laboratories now use the MDRD Study equation. 5 The National Kidney Foundation (NKF) has recommended that the CKD-EPI equation replace the MDRD Study equation in calculating eGFRs reported by clinical laboratories and in clinical practice, analogous to a software upgrade. 3, 6 The basis for this recommendation is that the new equation provides a more accurate estimate of GFR, especially at higher levels, and results in a decreased false-positive rate for the identification of CKD. In addition, because the CKD-EPI equation uses the same 4 variables as the MDRD Study equation, its use does not require that additional variables be collected by clinical laboratories.
The Kidney Early Evaluation Program (KEEP) is a free community-based health screening program that targets populations 18 years and older at high risk of kidney disease, defined as a history of diabetes or hypertension or first-order relative with diabetes, hypertension, or kidney disease. 7 The goal of KEEP is to screen for CKD in people at high risk of it. Thus, GFR estimates that are accurate in the higher range are particularly important for detecting incipient CKD in this population. As part of the NKF strategy to implement the CKD-EPI equation, a decision was made to use it to report eGFR in the KEEP population. Before implementing this change in KEEP, we sought to evaluate the impact of the new equation in the KEEP data set. In this study, we compare the 2 equations regarding the characteristics of patients identified with CKD and patients who died in this large cohort of people at high risk of CKD. We hypothesized that people with CKD classified using the CKD-EPI equation would be more likely to have risk factors for CKD and a higher risk of mortality.
METHODS

Study Participants
We included 123,704 eligible KEEP participants, August 2000 through December 31, 2009, from 48 NKF affiliates and 2,634 screening programs in 50 states and the District of Columbia. We excluded participants with missing CKD data, leaving a study population of 116,321. 
GFR Estimation
Definitions of CKD Risk Factors and Comorbid Conditions
Diabetes, hypertension, and older age are the primary risk factors for CKD identified in KEEP. Diabetes was defined as history of diabetes (self-report or retinopathy) or use of medications to treat diabetes. Hypertension was defined as history of hypertension (self-report) or use of medications to treat hypertension.
12 Coronary artery disease, congestive heart failure, stroke, and peripheral vascular disease were ascertained using self-report. Hemoglobin was measured for all participants, and anemia was defined using the World Health Organization definition; hemoglobin Ͻ13 g/dL for men and Ͻ12 g/dL for women.
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Ascertainment of Mortality
KEEP obtains informed consent from individual KEEP participants to use Social Security Number, first name, last name, and birth date in potential linkages for future research studies. All-cause mortality data in this study were ascertained by linking the KEEP study cohort to the first-quarter 2010 Social Security Administration Death Master File. All KEEP study participants were followed up through December 31, 2009, a median of 3.7 years of follow-up.
Statistical Analysis
Classification into eGFR categories was determined using both the MDRD Study and CKD-EPI equations for the overall study population and by CKD risk factors. Most analyses were descriptive, and 2 tests were used to compare CKD prevalence by risk factors by CKD status. Clinical characteristics of KEEP participants from 2000-2009 by eGFR categories according to the CKD-EPI equation are reported using frequencies and percentages. Prevalence of disease is reported by eGFR categories according to both the MDRD Study and CKD-EPI equations. Mortality expressed as deaths per 1,000 patient-years and confidence intervals (CIs) was calculated using eGFR categories. In calculating mortality, KEEP participants were followed up from the screening date to December 31, 2009, and censored at date of death. The standard error for CIs was calculated as the square root of number of deaths divided by total follow-up time in each category and expressed per 1,000 patient-years. To determine changes in participant characteristics and mortality within eGFR categories from one equation to the other, clinical characteristics and mortality were evaluated according to eGFR classification using each equation. For mortalAm J Kidney Dis. 2011;57(3)(suppl 2):S9-S16 S10 ity, the net reclassification index was calculated 14 as the sum of the proportion of participants reclassified downward to a lower eGFR category for people who died and the proportion of participants reclassified upward to a higher eGFR category for people who did not die minus the sum of the proportion of participants reclassified upward for people who died and the proportion of participants reclassified downward for people who did not die.
RESULTS
The median value for eGFR CKD-EPI was higher than for eGFR MDRD . Participants in lower eGFR categories determined using eGFR CKD-EPI were more likely to be older, male, and white and have higher blood pressure than participants in higher categories (Table 1) . They also were more likely to be anemic and have chronic conditions, such as diabetes, hypertension, coronary artery disease, congestive heart failure, and vascular disease. Similar results were observed for eGFR MDRD (Table S1 , provided as online supplementary material).
Using eGFR CKD-EPI , the overall prevalence of eGFR Ͻ60 mL/min/1.73 m 2 was 14.3% compared with 16.8% using eGFR MDRD Overall, participants reclassified to higher eGFR categories were more likely to be younger, female, and African American than participants not reclassified (Table S2 , provided as online supplementary material). Figure 1 shows changes in distributions of eGFR categories overall and by age. Participants who were reclassified upward also were less likely to have chronic conditions (Table 2 ). For example, compared with participants classified as eGFR of 45-59 mL/min/ Table 3 lists incidence rates for mortality for each eGFR category for both equations. The incidence rate for all-cause mortality for participants classified as eGFR of 45-59 mL/min/1.73 m 2 using both equations was 18.5 (95% CI, 17.1-19.9). The mortality incidence rate was lower at 6.4 (95% CI, 5.1-7.7) for participants with eGFR CKD-EPI of 60-89 mL/min/1.73 m 2 and higher at 47.6 (95% CI, 34.2-60.9) for participants with eGFR CKD-EPI of 30-44 mL/min/1.73 m 2 . The net reclassification index for improvement in risk of mortality was calculated (Table 4) . Of 3,601 participants who died, 242 (6.7%) were incorrectly reclassified to a higher GFR category using eGFR CKD-EPI . In contrast, of 112,720 participants who did not die, 20,113 (17.8%) were correctly reclassified to a higher eGFR category, for an overall net reclassification index of 0.159 (P Ͻ 0.001). The index varied by subgroup; for all subgroups except age, net reclassification index values ranged from 0.101-0.188 (P for all Ͻ 0.001). The net reclassification index was Ϫ0.010 (P ϭ 0.05) for participants younger than 45 years, 0.049 (P ϭ Ϫ0.003) for those aged 45-60 years, and 0.078 (P Ͻ 0.001) for those older than 60 years.
DISCUSSION
GFR is used in many clinical settings. In KEEP, it is used to identify people with CKD and assess CKD severity. In this study, we show that compared with the MDRD Study equation, use of the CKD-EPI equation resulted in a lower prevalence of eGFR Ͻ60 mL/min/1.73 m 2 and more participants classified to higher eGFR categories. Participants who were reclassified to higher categories using eGFR CKD-EPI were less likely to have CKD risk factors or comorbid conditions and were at lower risk of death compared with those who were classified to similar categories using both equations or reclassified to lower categories.
The 2 primary changes in the formulation of the CKD-EPI equation are use of a spline for serum creatinine level, which enables better identification of the differing relationships between creatinine level and GFR throughout the range of measured GFRs, and use of a linear instead of a logarithmic term for age. 3 The linear term for age leads to a steeper decrease in eGFR with age, such that people older than 70 years have a lower eGFR CKD-EPI than eGFR MDRD . These differences result in higher eGFRs for a given creatinine level compared with the MDRD Study equation for most people younger than ϳ75 years. The selective reclassification of people with CKD risk factors and comorbid conditions does not directly result from the formulation of the equation because these variables are not specifically included in the equation and likely reflects the association of age with these factors.
Recent studies in the general population compared the 2 equations with respect to CKD prevalence and Am J Kidney Dis. 2011;57(3)(suppl 2):S9-S16 S12 Note: All numbers are total; values are missing in each category. Conversion factor for eGFR in mL/min/1.73 m 2 to mL/s/1.73 m 2 , ϫ0.01667.
Abbreviations: CAD, coronary artery disease; CHF, congestive heart failure; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; CVD, cerebrovascular disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HTN, hypertension; KEEP, Kidney Early Evaluation Program; MDRD, Modification of Diet in Renal Disease; PVD, peripheral vascular disease.
a DM includes self-reported DM and using medication; HTN includes self-reported HTN and using medication; CAD includes history of heart attack, coronary artery bypass graft, angioplasty, and CAD; CHF data available starting 2005; CVD is defined as stroke; PVD includes PVD for 2000-2004 and limb amputation for 2005-2009. b Defined as hemoglobin level Ͻ13 g/dL for men and Ͻ12 g/dL for women. mortality risk. 3, 15, 16 The CKD-EPI equation leads to a lower estimated prevalence of CKD in the National Health and Nutrition Examination Survey (NHANES), 11.1% compared with 13.2% using the MDRD Study equation. In particular, people at lower risk of the development and progression of CKD, such as women, younger people, and whites, were more likely to be reclassified to higher GFR categories. 3 Analyses from the AusDiab 16 (Australian Diabetes, Obesity and Lifestyle) Study showed that people reclassified to higher eGFR categories had lower cardiovascular disease risk profiles and lower risk of the development of cardiovascular disease. A study of participants in the Atherosclerosis Risk in Communities (ARIC) Study showed that the CKD-EPI equation led to reclassification of ϳ45% of participants to higher GFR categories. 15 For those reclassified, risk was lower for mortality, end-stage renal disease, coronary heart disease, and stroke in eGFR categories Ͻ120 mL/min/1.73 m 2 . Our results extend the findings to a population at high risk of the development and progression of CKD and show that in this population, the CKD-EPI equation better categorizes people by eGFR consistent with their pre- Am J Kidney Dis. 2011;57(3)(suppl 2):S9-S16 S14 dicted risk of comorbid conditions commonly associated with CKD and of mortality.
In KEEP, people reclassified as eGFR CKD-EPI of 90-119 mL/min/1.73 m 2 had higher rates of CKD risk factors and comorbid conditions and lower risk of death compared with people classified as Ͼ120 mL/ min/1.73 m 2 using both equations. This is in contrast to studies that have shown that creatinine-based equations result in a J-shaped curve in the relationship between GFR and adverse outcomes, 17, 18 such that people classified as Ͼ120 mL/min/1.73 m 2 have a higher risk of death than people classified as 90-119 mL/min/1.73 m 2 . Consistent with these observations, in the ARIC analyses, people reclassified as eGFR CKD-EPI of 90-119 from Ͼ120 mL/min/1.73 m 2 had a lower rate of adverse events. 15 The likely explanation for the difference between the KEEP population and prior analyses relates to differences in characteristics of the populations. Possibly, people with eGFR Ͼ120 mL/ min/1.73 m 2 who are at high risk of adverse outcomes are too frail to participate in detection programs.
These findings have implications for KEEP, and similar implications would be expected for the general clinical population. Using the CKD-EPI equation, the prevalence of eGFR Ͻ60 mL/min/1.73 m 2 decreased by 20%. A major criticism of the CKD paradigm and use of the MDRD Study equation is that the underestimate of measured GFR using the MDRD Study equation leads to false-positive diagnoses, with subsequent anxiety imposed on people and excessive testing with consequent cost to the health care system. 19 These concerns are highly relevant for a detection program such as KEEP. KEEP sends letters to participants' physicians to verify positive results; thus, eGFR Ͻ60 mL/min/1.73 m 2 would result in further potentially unnecessary testing. In addition, the KEEP laboratory tests for abnormalities of mineral metabolism and other CKD complications only in people with eGFR Ͻ60 mL/min/1.73 m 2 . Thus, identification of fewer people will lead directly to cost savings for the program. Similar decisions and behaviors would occur for physicians caring for individual patients. The selective reclassification of high-versus low-risk groups suggests that GFR estimates using the CKD-EPI equation will enable better prognostication of patients' clinical courses.
Despite these improvements, the CKD-EPI equation is still based on serum creatinine level, allowing only a small improvement in precision compared with the MDRD Study equation. Additional markers may be required to further improve the precision of GFR estimates. At present, for patients at the extremes of muscle mass and diet or for whom highly accurate values are required for clinical decision making, confirmatory tests using clearance of exogenous markers or measured creatinine clearance are necessary. 20 The strength of this analysis is the large wellcharacterized cohort of people at risk of CKD. Limitations include use of only 1 serum creatinine measurement, preventing verification of CKD chronicity. However, KEEP bases its recommendations on 1 test, and this does not detract from the comparison of the equations. Second, comorbid conditions are defined using only self-report, leading to possible error in assignment of these conditions. Third, we were unable to evaluate complications of CKD other than anemia, such as hyperphosphatemia or hyperparathyroidism, because these were measured for only participants with eGFR MDRD Ͻ60 mL/min/1.73 m 2 and therefore were not ascertained uniformly for all participants.
In conclusion, the CKD-EPI equation resulted in reclassification to higher eGFR categories; participants reclassified to higher categories were less likely to have CKD risk factors or comorbid conditions and had a lower rate of death. More accurate identification of CKD is a major goal of a detection program and KEEP therefore will begin reporting eGFR using the CKD-EPI equation.
